Loading...
OTCM
PERCF
Market cap32mUSD
Mar 25, Last price  
0.00USD
Name

Antisense Therapeutics Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
3.49
EPS
—
Div Yield, %
—
Shrs. gr., 5y
26.65%
Rev. gr., 5y
-55.61%
Revenues
2m
-11.14%
000762,3686,399,0000000003,863,9881,000,00069,1150586,788668,433577,7641,777,9041,579,849
Net income
-11m
L+95.06%
-4,609,624-6,265,839-5,462,401-4,835,963-2,136,886-2,649,727-3,424,875-1,813,550-1,801,278-2,454,842-3,013,272706,918-2,514,443-2,754,799-2,331,015-2,305,862-5,890,210-8,067,192-5,834,080-11,379,828
CFO
-8m
L+4.44%
-2,209,608-5,585,305-3,958,499-2,679,528-3,401,498-3,283,821-1,336,627-1,867,239-2,405,200-2,833,186-3,107,8861,268,875-2,025,026-2,914,2220-2,928,436-3,945,358-5,834,156-7,805,166-8,151,329
Earnings
Aug 27, 2025

Profile

Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.
URL
https://www.antisense.com.au/
IPO date
Dec 20, 2001
Employees
8
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
1,580
-11.14%
Cost of revenue
14,573
Unusual Expense (Income)
NOPBT
(12,993)
NOPBT Margin
Operating Taxes
(377)
Tax Rate
NOPAT
(12,616)
Net income
(11,380)
95.06%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
94
Long-term debt
190
Deferred revenue
Other long-term liabilities
7
Net debt
(10,683)
Cash flow
Cash from operating activities
(8,151)
CAPEX
(29)
Cash from investing activities
(29)
Cash from financing activities
(85)
FCF
(11,650)
Balance
Cash
10,967
Long term investments
Excess cash
10,888
Stockholders' equity
9,976
Invested Capital
149
ROIC
ROCE
EV
Common stock shares outstanding
634,294
Price
0.06
-21.33%
Market cap
37,423
-21.33%
EV
26,740
EBITDA
(12,898)
EV/EBITDA
Interest
Interest/NOPBT